A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart

Urologic Consultants of Southeastern PA

Status and phase: Unknown; Phase 4

Conditions: Benign Prostatic Hyperplasia

Treatments: Drug: Dutasteride

Study type: Interventional

Funder types: Other

Identifiers

NCT00690950

110895

Details and patient eligibility

About

Hypothesis: Dutasteride will perform better than finasteride in decreasing prostate volume, improving symptoms based on International Prostate Symptom score,and lower pvr based on the scientific information that dutasteride inhibits both Type I and II 5-alpha-reducatase vs. finasteride which only inhibits the Type II enzyme

Enrollment: 50 estimated patients

Sex: Male

Ages: 50 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male
• Age 50-80
• On finasteride for no less than 12 months
• Willing to undergo all necessary test in the 12 month evaluation

Exclusion criteria

• History of medication non-compliance
• Unwillingness to undergo/tolerate 2 blood draws
• Unwillingness to tolerate/undergo 2 TRUSP

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)